The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Hummer, M.
* Articles by Fleischhacker, W. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Hummer, M.
* Articles by Fleischhacker, W. W.
Related Collections
* Neuroendocrinology
* Neurophysiology
* Atypical Neuroleptics
* Conventional Neuroleptics
* Schizophrenia Spectrum Disorders
Am J Psychiatry 162:162-167, January 2005
© 2005 American Psychiatric Association

Osteoporosis in Patients With Schizophrenia

Martina Hummer, M.D., Peter Malik, M.D., Rudolf W. Gasser, M.D., Alex Hofer, M.D., Georg Kemmler, Ph.D., Roy Cesar Moncayo Naveda, M.D., Maria A. Rettenbacher, M.D., and W. Wolfgang Fleischhacker, M.D.

OBJECTIVE: Osteoporosis is regularly mentioned as a possible consequence of treatment with prolactin-increasing antipsychotic medications, but little is known about the prevalence and the degree of loss of bone mineral density in patients suffering from schizophrenia. The authors’ goals were to investigate the association between schizophrenia and a decrease in bone mineral density and to get more insight into potential underlying pathophysiological mechanisms. METHOD: In a cross-sectional study, the authors used dual x-ray absorptiometry to determine bone mineral density of 75 inpatients and outpatients suffering from schizophrenia. All patients had been treated with antipsychotics for at least 1 year, and only patients between the ages of 19 and 50 were studied to exclude patients with age-related idiopathic osteoporosis. RESULTS: In men but not women with schizophrenia, bone mineral density was significantly lower than normal in the lumbar region. A comparison of loss of bone mineral density in male and female patients showed significant differences between the sexes. Bone mineral density showed a negative correlation with negative symptoms and Positive and Negative Syndrome Scale total score and a positive correlation with 25-hydroxy-vitamin D3 levels and body mass index in male patients. In female patients, a positive correlation between body mass index and bone mineral density was found. Exposure to prolactin-increasing antipsychotics was not related to bone mineral density. CONCLUSIONS: The male patients with schizophrenia in this study suffered from low bone density. This finding as well as other reports lend support to directing more attention to bone metabolism in patients with schizophrenia, although there is no universally accepted screening policy to identify individuals at high risk for osteoporosis.




This article has been cited by other articles:


Home page
Schizophr BullHome page
M. V. Seeman
Secondary Effects of Antipsychotics: Women at Greater Risk Than Men
Schizophr Bull, April 9, 2008; (2008) sbn023v1.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
C. Bushe, M. Shaw, and R. C Peveler
A review of the association between antipsychotic use and hyperprolactinaemia
J Psychopharmacol, March 1, 2008; 22(2_suppl): 46 - 55.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
C. Bushe, D. Yeomans, T. Floyd, and S. M Smith
Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics
J Psychopharmacol, March 1, 2008; 22(2_suppl): 56 - 62.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
M K. Javaid and R. I. Holt
Understanding osteoporosis
J Psychopharmacol, March 1, 2008; 22(2_suppl): 38 - 45.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
C. Bushe and M. Shaw
Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics
J Psychopharmacol, September 1, 2007; 21(7): 768 - 773.
[Abstract] [PDF]


Home page
Br. J. PsychiatryHome page
L. HOWARD, G. KIRKWOOD, and M. LEESE
Risk of hip fracture in patients with a history of schizophrenia
The British Journal of Psychiatry, February 1, 2007; 190(2): 129 - 134.
[Abstract] [Full Text] [PDF]


Home page
AutismHome page
R. Canitano and G. Vivanti
Tics and Tourette syndrome in autism spectrum disorders
Autism, January 1, 2007; 11(1): 19 - 28.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
J. LEVINE and R. H. BELMAKER
Osteoporosis and Schizophrenia
Am J Psychiatry, March 1, 2006; 163(3): 549 - 550.
[Full Text] [PDF]


Home page
JWatch PsychiatryHome page
Osteoporosis in Serious Psychiatric Disorders
Journal Watch Psychiatry, February 24, 2005; 2005(224): 3 - 3.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org